Comparison of the Amyloid Plaque Proteome in Down Syndrome, Early-Onset Alzheimer's Disease and Late-Onset Alzheimer's Disease.

BACKGROUND

Down syndrome (DS) is strongly associated with Alzheimer's disease (AD), attributable to overexpression. DS exhibits Amyloid-β (Aβ) and Tau pathology similar to early-onset AD (EOAD) and late-onset AD (LOAD). The study aimed to evaluate the Aβ plaque proteome of DS, EOAD and LOAD.

METHODS

Using unbiased localized proteomics, we analyzed amyloid plaques and adjacent plaque-devoid tissue ('non-plaque') from post-mortem paraffin-embedded tissues in four cohorts (n = 20/group): DS (59.8 ± 4.99 y/o), EOAD (63 ± 4.07 y/o), LOAD (82.1 ± 6.37 y/o) and controls (66.4 ± 13.04). We assessed functional associations using Gene Ontology (GO) enrichment and protein interaction networks.

RESULTS

We identified differentially abundant Aβ plaque proteins vs. non-plaques (FDR < 5%, fold-change > 1.5) in DS (n = 132), EOAD (n = 192) and in LOAD (n = 128); there were 43 plaque-associated proteins shared between all groups. Positive correlations ( < 0.0001) were observed between plaque-associated proteins in DS and EOAD (R = 0.77), DS and LOAD (R = 0.73), and EOAD vs. LOAD (R = 0.67). Top Biological process (BP) GO terms ( < 0.0001) included lysosomal transport for DS, immune system regulation for EOAD, and lysosome organization for LOAD. Protein networks revealed a plaque enriched signature across all cohorts involving APP metabolism, immune response, and lysosomal functions. In DS, EOAD and LOAD non-plaque vs. control tissue, we identified 263, 269, and 301 differentially abundant proteins, including 65 altered non-plaque proteins across all cohorts. Differentially abundant non-plaque proteins in DS showed a significant ( < 0.0001) but weaker positive correlation with EOAD (R = 0.59) and LOAD (R = 0.33) compared to the stronger correlation between EOAD and LOAD (R = 0.79). The top BP GO term for all groups was chromatin remodeling (DS = 0.0013, EOAD = 5.79×10, and LOAD = 1.69×10). Additional GO terms for DS included extracellular matrix ( = 0.0068), while EOAD and LOAD were associated with protein-DNA complexes and gene expression regulation ( < 0.0001).

CONCLUSIONS

We found strong similarities among the Aβ plaque proteomes in individuals with DS, EOAD and LOAD, and a robust association between the plaque proteomes and lysosomal and immune-related pathways. Further, non-plaque proteomes highlighted altered pathways related to chromatin structure and extracellular matrix (ECM), the latter particularly associated with DS. We identified novel Aβ plaque proteins, which may serve as biomarkers or therapeutic targets.